1. Home
  2. GECC vs MDXH Comparison

GECC vs MDXH Comparison

Compare GECC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GECC

Great Elm Capital Corp.

N/A

Current Price

$5.23

Market Cap

84.6M

Sector

Finance

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$0.55

Market Cap

68.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GECC
MDXH
Founded
2016
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
84.6M
68.7M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
GECC
MDXH
Price
$5.23
$0.55
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $10.75
$7.67
AVG Volume (30 Days)
61.0K
★ 206.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
★ 22.06%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.41
N/A
Revenue
N/A
N/A
Revenue This Year
$0.92
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
$12.88
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$0.40
52 Week High
$10.88
$5.33

Technical Indicators

Market Signals
Indicator
GECC
MDXH
Relative Strength Index (RSI) 34.61 34.24
Support Level $5.08 $0.51
Resistance Level $5.37 $0.75
Average True Range (ATR) 0.21 0.04
MACD -0.07 -0.02
Stochastic Oscillator 0.00 0.26

Price Performance

Historical Comparison
GECC
MDXH

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: